Flowstint in Podcasts
productFlowstint, a device treatment for benign prostatic hyperplasia, developed by Rivermark.
Mentions Over Time
1
mentions
Mentions in Podcasts
Medsider: Learn from Medtech and Healthtech Founders and CEOs
The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec
In this episode of MedCider, I sat down with Dr. Adam Kadlec, co-founder and CEO of Rivermark Medical, a urology-focused medtech company developing Flowstint, a first-line device treatment for benign prostatic hyperplasia, or BPH, as most of us know it.